Change in Preferred Drug List Status for Hypoglycemics, Insulin and Related Drug Class

Date: July 28, 2026

Attention: Providers

Effective date: July 27, 2026

Call to action: Effective July 27, 2026, the Texas Health and Human Services Commission (HHSC) temporarily removed the non-preferred status from certain insulin products on the Texas Medicaid Preferred Drug List (PDL). This temporary change was implemented in response to shipping delays and product backorder affecting Lantus SoloStar® due to high product demand. The update is intended to maintain access to necessary insulin therapy without requiring PDL prior authorization for the affected products.

How this impacts providers: The temporary change will allow providers to prescribe the affected insulin products without requiring PDL prior authorization at this time, helping maintain access to necessary insulin therapy for Texas Medicaid members during the Lantus SoloStar® supply disruption.

Next step for Providers: Prescribers are encouraged to proactively consider and prescribe the affected preferred alternatives, when clinically appropriate, to avoid disruption in therapy. Prescribers should share this communication with their staff.

If you have any questions, please email TCHP Pharmacy at: tchppharmacy@texaschildrens.org.

For access to all provider alerts www.texaschildrenshealthplan.org/for-providers.